BioSpace News Archive

Drug Development

Nuvalent Presents New Preclinical Data Supporting Potential Best-in-Class Profile for ALK-Selective Inhibitor NVL-655 at IASLC 2022 World Conference on Lung Cancer Annual Meeting

Nuvalent, Inc. announced new preclinical data supporting the potential best-in-class profile of NVL-655 – an ALK-selective inhibitor, and a “Trial in Progress” poster for the Phase 1/2 ARROS-1 study of NVL-520 – a ROS1-selective inhibitor.

August 5, 2022
·
12 min read
Pharm Country

Click Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that Randall Stanicky, Chief Financial Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 12:30 p.m. ET.

August 5, 2022
·
1 min read
Business

Forma Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today reported financial results for the second quarter ended June 30, 2022.

August 5, 2022
·
11 min read
Business

Aldeyra Therapeutics Reports Second-Quarter 2022 Financial Results and Recent Corporate Highlights

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases, today reported recent corporate highlights and financial results for the quarter ended June 30, 2022.

August 5, 2022
·
13 min read
Business

Twist Bioscience Reports Fiscal Third Quarter 2022 Financial Results

Twist Bioscience Corporation today reported financial results and business highlights for the third quarter of fiscal 2022 ended June 30, 2022.

August 5, 2022
·
12 min read
Business

Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Candel Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.

August 5, 2022
·
10 min read
Hyris’ New T-Cell Test is Finally Available to EU Countries to Easily Map Patients’ Cellular Immunity to SARS-CoV-2

As the pandemic crisis has entered a new phase, it is a common belief among the scientific community that COVID-19 is here to stay, maybe for a long time.

August 5, 2022
·
4 min read
Business

Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights

Nuvectis Pharma, Inc today reported its financial results for the second quarter of 2022 and provided an update on recent business progress.

August 5, 2022
·
9 min read
Pharm Country

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Aug 05, 2022

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 11 new employees.

August 5, 2022
·
1 min read
Business

Renowned Biopharma Leaders Join Newly Established Kallyope Clinical Development Advisory Board

Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the formation of its inaugural Clinical Development Advisory Board.

August 5, 2022
·
4 min read